toremifene
toremifene is a pharmaceutical drug with 22 clinical trials. Currently 1 active trials ongoing. Historical success rate of 72.7%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
57.1%
8 of 14 finished
42.9%
6 ended early
1
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Selective Estrogen Modulation and Melatonin in Early COVID-19
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer
Clinical Trials (22)
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Selective Estrogen Modulation and Melatonin in Early COVID-19
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer
Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Toremifene in Treating Patients With Ovarian Cancer
Estradiol-Receptor Blockade in Older Men and Women
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Toremifene in Treating Patients With Desmoid Tumors
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
Changes in Breast 3D Ultrasound Measurements Using Toremifene
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 22